Actively Recruiting
Open-label Phase II Study of LBL-024 Combined With Other Drugs for Advanced Solid Tumors Including Biliary Tract Cancer and Hepatocellular Carcinoma
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-10-19
140
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of LBL-024 with other drugs for treating patients with advanced biliary tract cancer and hepatocellular carcinoma, both types of advanced solid tumors. This open-label, phase II, multicenter study aims to assess the safety and effectiveness of these combination treatments in this patient population. Two groups of participants, called cohorts, are involved in this study to carefully monitor the treatments tolerability and impact. Participants in Cohort 1 receive LBL-024 combined with gemcitabine and cisplatin, while those in Cohort 2 receive LBL-024 combined with bevacizumab. Both treatment combinations are given through intravenous infusion. Each cohort begins with a 21-day safety observation period to evaluate tolerability. If the treatments are well tolerated, the study continues with additional participants receiving the combination therapies. Throughout the study, participants will be closely monitored with various tests and assessments, including laboratory evaluations and imaging to measure tumor response using RECIST 1.1 criteria. The main measurement is the objective response rate during and after treatment. Researchers will also assess disease control, duration of response, drug concentration levels, and immune response. The study plans to enroll up to 140 participants aged 18 to 75 years, with ongoing safety and efficacy follow-up until 28 days after treatment ends or before new anti-tumor therapy begins.
CONDITIONS
Brief Title
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Research Team
J
Jian zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here